Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Revenue (2016 - 2022)

Aptevo Therapeutics (APVO) has disclosed Revenue for 8 consecutive years, with $3.1 million as the latest value for Q1 2022.

  • Quarterly Revenue rose 28.62% to $3.1 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Dec 2022, down 74.67% year-over-year, with the annual reading at $3.1 million for FY2022, 74.67% down from the prior year.
  • Revenue hit $3.1 million in Q1 2022 for Aptevo Therapeutics, down from $3.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $9.0 million in Q4 2019 to a low of $473000.0 in Q2 2020.
  • Historically, Revenue has averaged $4.6 million across 5 years, with a median of $3.7 million in 2021.
  • Biggest five-year swings in Revenue: crashed 93.57% in 2020 and later skyrocketed 557.51% in 2021.
  • Year by year, Revenue stood at $5.8 million in 2018, then surged by 55.07% to $9.0 million in 2019, then crashed by 73.72% to $2.4 million in 2020, then soared by 54.45% to $3.7 million in 2021, then dropped by 15.03% to $3.1 million in 2022.
  • Business Quant data shows Revenue for APVO at $3.1 million in Q1 2022, $3.7 million in Q4 2021, and $3.1 million in Q3 2021.